The major strength of the study remains its large sample size of 192 individuals and caregivers, which is significant given the rarity of TSC, and the timing of this analysis after mTOR inhibitors were licensed for the treatment of various disease manifestations. Here, MTOR is linked to tuberous sclerosis.